Moreover, several EGFR-TKIs, such as gefitinib, erlotinib, and afatinib, were found to be superior to standard chemotherapy (carboplatin-paclitaxel, cisplatin-docetaxel, or platinum-pemetrexed) as an initial treatment for patients with EGFR mutation-positive advanced lung adenocarcinoma/NSCLC in terms of progression-free survival (PFS) and quality of life [4–7]. Here, EGFR is linked to non-small cell lung carcinoma.